Anna Alekseevna Osipova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anna Alekseevna Osipova has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Lyudmila Stepanovna Zubarovskaya
I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Health of the Russian Federation
16 shared publications - Aleksander Dmitrievich Kulagin
Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
13 shared publications - Tatiana Alexandrovna Bykova
I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation
12 shared publications - Olesya Vladimirovna Paina
I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Health of the Russian Federation
11 shared publications - Elena Vladimirovna Semenova
The R.M. Gorbacheva Research Institute for Pediatric Oncology, Hematology and Transplantation of the I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation
10 shared publications - Lubov Alexandrovna Tsvetkova
Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg, Ministry of Health of Russia
8 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (2) , 25-36
Factors determining successful allogeneic hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes
Introduction. Inherited bone marrow failure syndromes (IBMFS) constitute a heterogeneous group of rare genetic disorders associated with impaired hematopoiesis, congenital anomalies, and a high risk of transformation to myelodysplastic syndrome and acute myeloid leukemia. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for IBMFS. Aim: to identify factors determining the efficacy of allo-HSCT in pediatric patients with IBMFS. Materials and methods. This study analyzed data from 61 patients with IBMFS who had undergone allo-HSCT between 2005 and 2025 at the R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation. Results. The median follow-up was 24 months. The overall survival (OS) at 1, 3, and 5 years post-transplantation was 88%, 85%, and 81%, respectively. The lowest 5-year OS was observed in the Fanconi anemia (47%) and Diamond–Blackfan anemia (86%) groups, whereas in the patients with other IBMFS the 5-year OS reached 100% (p = 0.003). Factors associated with improved survival included age younger than 5 years at transplantation (100% vs. 68%; p = 0.009), the use of myeloablative conditioning regimens (100% vs. 64.5%; p = 0.002), the use of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis (100% vs. 67%; p = 0.02), and successful engraftment (88% vs. 33%; p = 0.002). GVHD prophylaxis regimens without calcineurin inhibitors were associated with a lower incidence of grade II–IV acute GVHD (11% vs. 44%; p = 0.03) and a reduced need for switching immunosuppression (5% vs. 35%; p = 0.02). Donor type and degree of HLA matching did not significantly affect survival. Conclusion. Allo-HSCT is a highly effective treatment for children with IBMFS, providing a 5-year OS of 81%. The best outcomes are achieved with allo-HSCT performed at an early age (under 5 years), the use of myeloablative conditioning regimens (when not contraindicated), and with the addition of PTCy to GVHD prophylaxis. The lowest survival was observed in the patients with Fanconi anemia, highlighting the need for further refinement of treatment protocols for this patient group. PTCy-based GVHD prophylaxis regimens without calcineurin inhibitors reduce the incidence of acute GVHD and improve the tolerability of immunosuppression.
- 30 June 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (2) , 25-36
Open AccessFactors determining successful allogeneic hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes
Introduction. Inherited bone marrow failure syndromes (IBMFS) constitute a heterogeneous group of rare genetic disorders associated with impaired hematopoiesis, congenital anomalies, and a high risk of transformation to myelodysplastic syndrome and acute myeloid leukemia. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for IBMFS. Aim: to identify factors determining the efficacy of allo-HSCT in pediatric patients with IBMFS. Materials and methods. This study analyzed data from 61 patients with IBMFS who had undergone allo-HSCT between 2005 and 2025 at the R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation. Results. The median follow-up was 24 months. The overall survival (OS) at 1, 3, and 5 years post-transplantation was 88%, 85%, and 81%, respectively. The lowest 5-year OS was observed in the Fanconi anemia (47%) and Diamond–Blackfan anemia (86%) groups, whereas in the patients with other IBMFS the 5-year OS reached 100% (p = 0.003). Factors associated with improved survival included age younger than 5 years at transplantation (100% vs. 68%; p = 0.009), the use of myeloablative conditioning regimens (100% vs. 64.5%; p = 0.002), the use of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis (100% vs. 67%; p = 0.02), and successful engraftment (88% vs. 33%; p = 0.002). GVHD prophylaxis regimens without calcineurin inhibitors were associated with a lower incidence of grade II–IV acute GVHD (11% vs. 44%; p = 0.03) and a reduced need for switching immunosuppression (5% vs. 35%; p = 0.02). Donor type and degree of HLA matching did not significantly affect survival. Conclusion. Allo-HSCT is a highly effective treatment for children with IBMFS, providing a 5-year OS of 81%. The best outcomes are achieved with allo-HSCT performed at an early age (under 5 years), the use of myeloablative conditioning regimens (when not contraindicated), and with the addition of PTCy to GVHD prophylaxis. The lowest survival was observed in the patients with Fanconi anemia, highlighting the need for further refinement of treatment protocols for this patient group. PTCy-based GVHD prophylaxis regimens without calcineurin inhibitors reduce the incidence of acute GVHD and improve the tolerability of immunosuppression.
- Open Access
- 20 January 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (4) , 35-43
Results of therapy for relapse associated with the loss HLA of heterozygosity in children with acute leukemia
Introduction. The prognosis for patients with relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains extremely unfavorable, with long-term overall survival (OS) rates less than 10 %. One of the major acquired mechanisms of immunological resistance is loss heterozygosity of HLA (LoH) genes located on chromosome 6. For patients who have developed HLA LoH relapse, immunotherapy based on independent antigen recognition pathways such as blinatumomab therapy, CAR-T therapy or second allo-HSCT is being considered.The aim of the study – to analyze the efficacy of immunotherapy options in children with HLA LoH relapse based on donor lymphocyte infusions (DLI), blinatumomab and second allo-HSCT.Materials and methods. We have analyzed 26 patients with HLA LoH confirmed relapse with bone marrow involvement after allo-HSCT. Acute myeloid leukemia was detected in 6 (23 %) patients, acute lymphoblastic leukemia (ALL) in 20 (77 %) patients (B-ALL in 16 patients, T-ALL in 4 patients). Most patients were observed after allo-HSCT from a haploidentical donor, in 24 (92 %) patients and 2 (7.6 %) patients developed relapse after allo-HSCT from a full matched related donor. Isolated medullary relapse was diagnosed in 20 patients; combined relapse was noted in 6 patients (with CNS involvement in 5 patients, testicular relapse in 1 patient).Results. In the bispecific T-cell activator immunotherapy group, 5 patients with ALL received blinatumomab. Blinatumomab in combination with DLI was given to 3 patients. A response to therapy by the clinical and hematological remission was observed in all patients. MRD negative status was achieved in 4 patients. Subsequently, 2 patients developed medullary relapse and died of the disease progression; 1 patient died of neurotoxic complications after second allo-HSCT; 2 patients are alive in remission after the second allo-HSCT, with follow-up of 10 and 4 months. Second allo-HSCT was performed in 8 patients, with donor change in 7 patients. In the comparable analysis of the efficacy of HLA LoH relapse therapy, the 2-year OS in the second allo-HSCT group was 71.4 %, compared to 26.3 % in patients who did not undergo second allo-HSCT with donor change (p = 0.06). Comparing the OS results of patients with second allo-HSCT (n = 7), DLI (n = 8) and other therapy (n = 11), the favorable effect was seen by the second allo-HSCT group, where the OS was 71.4 %, 25 % and 27.3 % respectively (p = 0.045).Conclusion. The presented analysis of the efficacy of different therapeutic options for HLA LoH relapse shows a significant benefit of the second allo-HSCT in this cohort. The investigation of loss of HLA (LoH) heterozygosity in relapse after allo-HSCT in routine practice may differentiate approaches to relapse therapy and decrease the time frame for the second allo-HSCT.
- 20 January 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (4) , 35-43
Open AccessResults of therapy for relapse associated with the loss HLA of heterozygosity in children with acute leukemia
Introduction. The prognosis for patients with relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains extremely unfavorable, with long-term overall survival (OS) rates less than 10 %. One of the major acquired mechanisms of immunological resistance is loss heterozygosity of HLA (LoH) genes located on chromosome 6. For patients who have developed HLA LoH relapse, immunotherapy based on independent antigen recognition pathways such as blinatumomab therapy, CAR-T therapy or second allo-HSCT is being considered.The aim of the study – to analyze the efficacy of immunotherapy options in children with HLA LoH relapse based on donor lymphocyte infusions (DLI), blinatumomab and second allo-HSCT.Materials and methods. We have analyzed 26 patients with HLA LoH confirmed relapse with bone marrow involvement after allo-HSCT. Acute myeloid leukemia was detected in 6 (23 %) patients, acute lymphoblastic leukemia (ALL) in 20 (77 %) patients (B-ALL in 16 patients, T-ALL in 4 patients). Most patients were observed after allo-HSCT from a haploidentical donor, in 24 (92 %) patients and 2 (7.6 %) patients developed relapse after allo-HSCT from a full matched related donor. Isolated medullary relapse was diagnosed in 20 patients; combined relapse was noted in 6 patients (with CNS involvement in 5 patients, testicular relapse in 1 patient).Results. In the bispecific T-cell activator immunotherapy group, 5 patients with ALL received blinatumomab. Blinatumomab in combination with DLI was given to 3 patients. A response to therapy by the clinical and hematological remission was observed in all patients. MRD negative status was achieved in 4 patients. Subsequently, 2 patients developed medullary relapse and died of the disease progression; 1 patient died of neurotoxic complications after second allo-HSCT; 2 patients are alive in remission after the second allo-HSCT, with follow-up of 10 and 4 months. Second allo-HSCT was performed in 8 patients, with donor change in 7 patients. In the comparable analysis of the efficacy of HLA LoH relapse therapy, the 2-year OS in the second allo-HSCT group was 71.4 %, compared to 26.3 % in patients who did not undergo second allo-HSCT with donor change (p = 0.06). Comparing the OS results of patients with second allo-HSCT (n = 7), DLI (n = 8) and other therapy (n = 11), the favorable effect was seen by the second allo-HSCT group, where the OS was 71.4 %, 25 % and 27.3 % respectively (p = 0.045).Conclusion. The presented analysis of the efficacy of different therapeutic options for HLA LoH relapse shows a significant benefit of the second allo-HSCT in this cohort. The investigation of loss of HLA (LoH) heterozygosity in relapse after allo-HSCT in routine practice may differentiate approaches to relapse therapy and decrease the time frame for the second allo-HSCT.
- Open Access
- 13 December 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (4) , 95-106
Immunoadoptive effect of donor lymphocyte infusion-induced acute graft-versus-host disease in children with acute leukemia
Donor lymphocyte infusion (DLI) for prophylactic purposes enhances the immunoadoptive antitumor effect, thereby reducing the risk of relapse after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute leukemia. One of the main limiting factors for the use of DLI is the risk of developing graft-versus-host disease (GVHD). According to studies, the incidence of this complication of DLI ranges from 15% to 45% for acute GVHD (aGVHD) and from 10% to 50% for the chronic form. The development of GVHD after DLI also leads to enhancement of the antitumor effect and reduces the risk of relapse. At the same time, an increased risk of relapse is associated with the loss of HLA heterozygosity after haploidentical HSCT, and the role of GVHD in this process has not been investigated yet. In this single-center retrospective study, we performed a comparative analysis of the risk of bone marrow and extramedullary relapses in pediatric patients with acute lymphoblastic leukemia and acute myeloid leukemia who had received prophylactic DLI after allogeneic HSCT. We also assessed the severity of DLI-induced aGVHD and the incidence and severity of chronic GVHD, and investigated the relationship between aGVHD and the loss of HLA heterozygosity. We identified two groups of patients: those who had received prophylactic DLI (an intervention group; n = 41) and those who had not (a comparison group; n = 46). Informed consent to the inclusion in the study was obtained from all the patients/legal representatives. Protocol (No. 249 dated 31.05.2021) was registered in the Ethics Committee of the I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation. All the patients were divided into four subgroups according the use of IDL and the development of aGVHD: +DLI – patients with DLI and without aGVHD (n = 34); +DLIGVHD – patients with DLI-induced aGVHD (n = 7); –DLI – patients without DLI and aGVHD (n = 34); –DLIGVHD – patients without DLI and with a history of aGVHD (n = 12). A total of 7 (17%) cases of DLI-induced aGVHD were recorded. There were no statistically significant differences in the incidence and severity of gastrointestinal tract involvement (p = 1) and liver involvement (p = 0.75) between the 2 groups. The incidence of grade III–IV skin GVHD (p = 0.06) was higher in the non-DLI group. No deaths associated with DLI-induced GVHD were recorded. The median number of aGVHD treatment lines (2 (1–4) and 1 (1–2); p = 0.2) and the duration of treatment (63 (23–1455) days and 70 (44–111) days; p = 0.72) were similar in the 2 groups. The incidence of chronic GVHD in the DLI group (n = 7; 17%) and in the comparison group (n = 12; 26%) did not differ significantly (p = 0.45). The cumulative incidence of bone marrow relapses was significantly lower in those patients who developed aGVHD, after DLI or without DLI (–DLI 63% (95% confidence interval (CI) 43–77), +DLI 41% (95% CI 24–57), –DLIGVHD 21% (95% CI 5–46), +DLIGVHD 14% (1–50%) (p = 0.003)). There were no significant differences between the study groups in terms of the cumulative incidence of extramedullary relapses that ranged from 16% to 29% (p = 0.8). The overall survival of the patients with aGVHD (from the –DLIGVHD and +DLIGVHD groups) was 86% (95% CI 33–98) and 84% (95% CI 50–96), respectively, and it was statistically significantly different from the overall survival of the patients without aGVHD: 54% (95% CI 35–70) and 38% (95% CI 20–56) in the +DLI and –DLI subgroups, respectively (p = 0.012). The loss of HLA heterozygosity was evaluated in 22 (40%) out of 55 patients with a post-transplant relapse. In total, HLA haplotype loss was detected in 7 (32%) patients, 3 of whom were from the +DLI group (42.9%), 2 from the –DLI group (28.6%), and another 2 from the –DLIGVHD group (28.6%). Out of 15 individuals without HLA loss, one patient (6.7%) had a history aGVHD and did not receive DLI (p = 0.57). Thus, prophylactic DLI in children with acute lymphoblastic leukemia and acute myeloid leukemia is shown to be effective in preventing bone marrow relapses after allogeneic HSCT. The development of aGVHD has a potentiating effect resulting in increased immunoadoptive activity of donor lymphocytes. The severity and clinical manifestations of DLI-induced aGVHD in pediatric patients do not differ significantly from those patients who develop classical aGVHD early after transplantation.
- 13 December 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (4) , 95-106
Open AccessImmunoadoptive effect of donor lymphocyte infusion-induced acute graft-versus-host disease in children with acute leukemia
Donor lymphocyte infusion (DLI) for prophylactic purposes enhances the immunoadoptive antitumor effect, thereby reducing the risk of relapse after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute leukemia. One of the main limiting factors for the use of DLI is the risk of developing graft-versus-host disease (GVHD). According to studies, the incidence of this complication of DLI ranges from 15% to 45% for acute GVHD (aGVHD) and from 10% to 50% for the chronic form. The development of GVHD after DLI also leads to enhancement of the antitumor effect and reduces the risk of relapse. At the same time, an increased risk of relapse is associated with the loss of HLA heterozygosity after haploidentical HSCT, and the role of GVHD in this process has not been investigated yet. In this single-center retrospective study, we performed a comparative analysis of the risk of bone marrow and extramedullary relapses in pediatric patients with acute lymphoblastic leukemia and acute myeloid leukemia who had received prophylactic DLI after allogeneic HSCT. We also assessed the severity of DLI-induced aGVHD and the incidence and severity of chronic GVHD, and investigated the relationship between aGVHD and the loss of HLA heterozygosity. We identified two groups of patients: those who had received prophylactic DLI (an intervention group; n = 41) and those who had not (a comparison group; n = 46). Informed consent to the inclusion in the study was obtained from all the patients/legal representatives. Protocol (No. 249 dated 31.05.2021) was registered in the Ethics Committee of the I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation. All the patients were divided into four subgroups according the use of IDL and the development of aGVHD: +DLI – patients with DLI and without aGVHD (n = 34); +DLIGVHD – patients with DLI-induced aGVHD (n = 7); –DLI – patients without DLI and aGVHD (n = 34); –DLIGVHD – patients without DLI and with a history of aGVHD (n = 12). A total of 7 (17%) cases of DLI-induced aGVHD were recorded. There were no statistically significant differences in the incidence and severity of gastrointestinal tract involvement (p = 1) and liver involvement (p = 0.75) between the 2 groups. The incidence of grade III–IV skin GVHD (p = 0.06) was higher in the non-DLI group. No deaths associated with DLI-induced GVHD were recorded. The median number of aGVHD treatment lines (2 (1–4) and 1 (1–2); p = 0.2) and the duration of treatment (63 (23–1455) days and 70 (44–111) days; p = 0.72) were similar in the 2 groups. The incidence of chronic GVHD in the DLI group (n = 7; 17%) and in the comparison group (n = 12; 26%) did not differ significantly (p = 0.45). The cumulative incidence of bone marrow relapses was significantly lower in those patients who developed aGVHD, after DLI or without DLI (–DLI 63% (95% confidence interval (CI) 43–77), +DLI 41% (95% CI 24–57), –DLIGVHD 21% (95% CI 5–46), +DLIGVHD 14% (1–50%) (p = 0.003)). There were no significant differences between the study groups in terms of the cumulative incidence of extramedullary relapses that ranged from 16% to 29% (p = 0.8). The overall survival of the patients with aGVHD (from the –DLIGVHD and +DLIGVHD groups) was 86% (95% CI 33–98) and 84% (95% CI 50–96), respectively, and it was statistically significantly different from the overall survival of the patients without aGVHD: 54% (95% CI 35–70) and 38% (95% CI 20–56) in the +DLI and –DLI subgroups, respectively (p = 0.012). The loss of HLA heterozygosity was evaluated in 22 (40%) out of 55 patients with a post-transplant relapse. In total, HLA haplotype loss was detected in 7 (32%) patients, 3 of whom were from the +DLI group (42.9%), 2 from the –DLI group (28.6%), and another 2 from the –DLIGVHD group (28.6%). Out of 15 individuals without HLA loss, one patient (6.7%) had a history aGVHD and did not receive DLI (p = 0.57). Thus, prophylactic DLI in children with acute lymphoblastic leukemia and acute myeloid leukemia is shown to be effective in preventing bone marrow relapses after allogeneic HSCT. The development of aGVHD has a potentiating effect resulting in increased immunoadoptive activity of donor lymphocytes. The severity and clinical manifestations of DLI-induced aGVHD in pediatric patients do not differ significantly from those patients who develop classical aGVHD early after transplantation.
- Open Access
- 11 August 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (2) , 40-53
Oral nutritional supplements tolerance and compliance in pediatric oncology
Introduction. Patients treated with chemotherapy and hematopoietic stem cell transplantation (HSCT) often suffer from complications that have a negative impact on appetite and the functional ability of the digestive system, which can lead to the malnutrition – a factor of poor overall survival prognosis in hematology. Oral nutritional supplementation is one of the nutrition support (NS) types, which is currently developing by improving the taste properties and optimizing formula chemical composition, but is an underestimated NS option in clinical practice.The aim of the study – to evaluate oral nutritional supplements (ONS) tolerability and compliance in pediatric oncology patients during anticancer treatment.Materials and methods. From 2015 to 2022, in the Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg, Ministry of Health of Russia 988 cases of oral nutritional supplementation in patients from birth to 18 years old, with acute leukemia – 49.5 % (n = 489), hereditary diseases – 17.4 % (n = 172) and solid tumors – 16.9 % (n = 167) were included to a retrospective analysis. The median age was 7 (3–13) years. Male patients were in 61 % of cases (n = 603), female patients – 39 % (n = 385). In 74.2 % of cases (n = 733) allogeneic HSCT was used as a treatment option, in 22.4 % (n = 221) chemotherapy and autologous HSCT, in 3.4 % (n = 34) surgery, 11 of them as a primary tumor removal, 23 as a part of the main treatment’s complications cure. At the time of sipping initiation in 50.7 % of cases (n = 501), there was hyporexia, in 26.8 % of cases (n = 265) maldigestion, in 27.2 % (n = 269) malabsorption. In 54.6 % of cases (n = 203), a chronic graft-versus-host disease (GVHD) was observed, including the mucous membranes and gastrointestinal tract involvement. In 1.8 % of cases (n = 18), ONS was used in combination with breastfeeding, in 2.8 % (n = 28) with enteral nutrition and in 15.1 % (n = 149) with parenteral nutrition. The formula composition included standard (n = 766), semi-elemental (n = 97), balanced infant formula (n = 89) and specialized (n = 36) samples. The sipping usage in the relation of HSCT onset was preventive (n = 130), in the early period – up to D+30 (n = 212), D+31–100 (n = 182), D > +101 (n = 400).Results. Good ONS tolerability in the general cohort of patients was in 96.1 % (n = 948). Cases of poor tolerance were noted in 3.9 % of patients (n = 38). The factors that matched children with reduced sipping tolerance compared with acceptable one were: age – median 13.5 (4.0; 15.8, Q1 –Q3 ) and 7 (3.0; 12.0, Q1 –Q3 ) years, p = 0.002; presence of chronic GVHD – 91.3 % (n = 21) and 52 % (n = 181), p = 0.001; unpleasant formula taste – 42.1 % (n = 16) and 12.1 % (n = 115), p < 0.001, respectively. The effectiveness of sipping was evaluated before and after therapy based on the dynamics of body mass index (BMI) in three age groups: 14.5 (13.1; 16, Q1 –Q3 ) and 14.5 (13.4; 16.0, Q1 –Q3 ) in patients 2–8 years old, p = 0.12; 15.2 (13.7; 17.3, Q1 –Q3 ) and 14.7 (13.6 and 16.4, Q1 –Q3 ) in patients 9–12 years old, p = 0.009; 17.1 (14.6 and 19.9, Q1 –Q3 ) and 16.3 (14.3 and 18.4, Q1 –Q3 ) in patients aged 13–18 years, p = 0.0000. These results indicate that oral nutritional supplementation alone or as part of NS allow maintaining BMI within the average age standards, but only in younger patients in comparison with adolescents. In the group of patients with allogeneic HSCT (n = 731) in comparison with the general cohort of patients included in the follow-up, reduced ONS tolerance was determined somewhat more often – in 4.5 % of cases (n = 33). Chronic GVHD (91.3 %, n = 21, p = 0.001) was identified among the factors influencing the risk of developing reduced formula tolerance, while hyporexia (36.4 %, n = 12, p = 0.28), maldigestion (30.3 %, n = 10, p = 0.73) and malabsorption (42.4 %, n = 14, p = 0.1) did not have a negative effect. In 86.7 % of cases, patients characterized the sipping taste like: “I enjoy it”; and in infants, the criterion of adequate compliance was the absence of baby bottle rejection. Among the subjects who used sipping for more than one week with a pleasant taste for them (n = 810), 8.8 % (n = 79) developed formula rejection. In the group of patients with reduced compliance (n = 131) – who initially did not like the ONS taste and texture – an increase in the frequency of poor tolerability was noted from 2.6 to 12.2 % (n = 16), p < 0.001. Combined NS was also more often required: enteral nutrition 1.6 % (n = 14) and 10.7 % (n = 14), parenteral nutrition – 13.2 % (n = 113) and 27.5 % (n = 36), respectively, p < 0.001. Conclusions. Oral nutritional supplementation is an essential part of NS in pediatric oncology and hereditary diseases treatment, including the HSCT, which, on the example of patients with malfunctioned digestive system, has an appropriate tolerance and compliance.
- 11 August 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (2) , 40-53
Open AccessOral nutritional supplements tolerance and compliance in pediatric oncology
Introduction. Patients treated with chemotherapy and hematopoietic stem cell transplantation (HSCT) often suffer from complications that have a negative impact on appetite and the functional ability of the digestive system, which can lead to the malnutrition – a factor of poor overall survival prognosis in hematology. Oral nutritional supplementation is one of the nutrition support (NS) types, which is currently developing by improving the taste properties and optimizing formula chemical composition, but is an underestimated NS option in clinical practice.The aim of the study – to evaluate oral nutritional supplements (ONS) tolerability and compliance in pediatric oncology patients during anticancer treatment.Materials and methods. From 2015 to 2022, in the Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg, Ministry of Health of Russia 988 cases of oral nutritional supplementation in patients from birth to 18 years old, with acute leukemia – 49.5 % (n = 489), hereditary diseases – 17.4 % (n = 172) and solid tumors – 16.9 % (n = 167) were included to a retrospective analysis. The median age was 7 (3–13) years. Male patients were in 61 % of cases (n = 603), female patients – 39 % (n = 385). In 74.2 % of cases (n = 733) allogeneic HSCT was used as a treatment option, in 22.4 % (n = 221) chemotherapy and autologous HSCT, in 3.4 % (n = 34) surgery, 11 of them as a primary tumor removal, 23 as a part of the main treatment’s complications cure. At the time of sipping initiation in 50.7 % of cases (n = 501), there was hyporexia, in 26.8 % of cases (n = 265) maldigestion, in 27.2 % (n = 269) malabsorption. In 54.6 % of cases (n = 203), a chronic graft-versus-host disease (GVHD) was observed, including the mucous membranes and gastrointestinal tract involvement. In 1.8 % of cases (n = 18), ONS was used in combination with breastfeeding, in 2.8 % (n = 28) with enteral nutrition and in 15.1 % (n = 149) with parenteral nutrition. The formula composition included standard (n = 766), semi-elemental (n = 97), balanced infant formula (n = 89) and specialized (n = 36) samples. The sipping usage in the relation of HSCT onset was preventive (n = 130), in the early period – up to D+30 (n = 212), D+31–100 (n = 182), D > +101 (n = 400).Results. Good ONS tolerability in the general cohort of patients was in 96.1 % (n = 948). Cases of poor tolerance were noted in 3.9 % of patients (n = 38). The factors that matched children with reduced sipping tolerance compared with acceptable one were: age – median 13.5 (4.0; 15.8, Q1 –Q3 ) and 7 (3.0; 12.0, Q1 –Q3 ) years, p = 0.002; presence of chronic GVHD – 91.3 % (n = 21) and 52 % (n = 181), p = 0.001; unpleasant formula taste – 42.1 % (n = 16) and 12.1 % (n = 115), p < 0.001, respectively. The effectiveness of sipping was evaluated before and after therapy based on the dynamics of body mass index (BMI) in three age groups: 14.5 (13.1; 16, Q1 –Q3 ) and 14.5 (13.4; 16.0, Q1 –Q3 ) in patients 2–8 years old, p = 0.12; 15.2 (13.7; 17.3, Q1 –Q3 ) and 14.7 (13.6 and 16.4, Q1 –Q3 ) in patients 9–12 years old, p = 0.009; 17.1 (14.6 and 19.9, Q1 –Q3 ) and 16.3 (14.3 and 18.4, Q1 –Q3 ) in patients aged 13–18 years, p = 0.0000. These results indicate that oral nutritional supplementation alone or as part of NS allow maintaining BMI within the average age standards, but only in younger patients in comparison with adolescents. In the group of patients with allogeneic HSCT (n = 731) in comparison with the general cohort of patients included in the follow-up, reduced ONS tolerance was determined somewhat more often – in 4.5 % of cases (n = 33). Chronic GVHD (91.3 %, n = 21, p = 0.001) was identified among the factors influencing the risk of developing reduced formula tolerance, while hyporexia (36.4 %, n = 12, p = 0.28), maldigestion (30.3 %, n = 10, p = 0.73) and malabsorption (42.4 %, n = 14, p = 0.1) did not have a negative effect. In 86.7 % of cases, patients characterized the sipping taste like: “I enjoy it”; and in infants, the criterion of adequate compliance was the absence of baby bottle rejection. Among the subjects who used sipping for more than one week with a pleasant taste for them (n = 810), 8.8 % (n = 79) developed formula rejection. In the group of patients with reduced compliance (n = 131) – who initially did not like the ONS taste and texture – an increase in the frequency of poor tolerability was noted from 2.6 to 12.2 % (n = 16), p < 0.001. Combined NS was also more often required: enteral nutrition 1.6 % (n = 14) and 10.7 % (n = 14), parenteral nutrition – 13.2 % (n = 113) and 27.5 % (n = 36), respectively, p < 0.001. Conclusions. Oral nutritional supplementation is an essential part of NS in pediatric oncology and hereditary diseases treatment, including the HSCT, which, on the example of patients with malfunctioned digestive system, has an appropriate tolerance and compliance.
- Open Access
- 8 July 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 60-70
Inotuzumab ozogamicin as a bridging therapy to allogeneic hematopoietic stem cell transplantation in children with refractory/relapsed B-cell acute lymphoblastic leukemia
In children with acute lymphoblastic leukemia (ALL), relapse is still the leading cause of treatment failure occurring in 10–15% of cases. Overall survival after relapse plateaus at 50–60%, whereas event-free survival after second and third relapse is approximately 25% and 15%, respectively. The introduction of new immunotherapeutic agents such as blinatumomab (a bispecific T-cell engager), inotuzumab ozogamicin (InO; a CD22+ monoclonal antibody) and a chimeric antigen T-cell receptor targeted to CD19+ can significantly increase the effectiveness of treatment for relapsed ALL and help patients achieve remission faster and thus shorten the time to allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the toxicity of these novel agents and their impact on the results of allo-HSCT are still to be investigated. Our study included 55 patients with refractory B-cell ALL aged from 3 to 17 years (the median age was 10 years). The study was approved by the Independent Ethics Committee and the Scientific Council of the I.P. Pavlov First Saint Petersburg State Medical University. The patients were divided into two groups based on whether they received inotuzumab ozogamicin or not: InO+ group (n = 24; 43.6%) and InO– group (n = 31; 56.4%). The majority of the patients underwent haploidentical HSCT (n = 53; 96.4%); 1 (1.8%) patient received HSCT from a matched related donor, and 1 (1.8%) from a matched unrelated donor. Conditioning regimens before allo-HSCT included: myeloablative conditioning (n = 20; 36.4%), reduced toxicity myeloablative conditioning (n = 5; 9.1%), and reduced intensity conditioning (n = 30; 54.5%). Acute graft-versus-host disease prophylaxis with post-transplant cyclophosphamide was given to 49 (87.7%) recipients; 6 (12.3%) patients received seroprophylaxis. Basic combined immunosuppressive therapy consisting of a calcineurin inhibitor and an mTOR inhibitor was used in 35 (63.6%) cases, and single m-TOR inhibitor treatment was administered to 20 (36.4%) patients. In the InO+ group, 21 (87.5%) patients achieved complete remission with incomplete hematologic recovery before allo-HSCT: 5 (23.8%) patients had minimal residual disease (MRD), and 16 (76.2%) patients were MRD negative. In the InO– group, remission with incomplete hematologic recovery before allo-HSCT was achieved in 15 (48.4%) patients: 3 (9.7%) cases were MRD positive and 12 (38.7%) were MRD negative (p = 0.003). All the patients underwent allo-HSCT, regardless of response to prior therapy. Engraftment was achieved in the InO+ group in 20 (83.3%) children in a median of 22 days (D+22) and in the InO– group in 25 (80.6%) children in a median of 19 days (D+19). Relapse was observed in 11 (55%) patients in the InO+ group and in 15 (60%) patients in the InO– group at a median of 164 days and 203 days post-transplant, respectively (p = n. s.). In the InO+ group, 5 (31.25%) out of 16 patients in complete remission with incomplete hematologic recovery and negative MRD status relapsed after allo-HSCT within a median of 105 days (D+58 – D+169). In the InO–, 6 (50%) out of 12 patients in complete remission with incomplete hematologic recovery and negative MRD status relapsed within a median of 296 days (D+108 – D+929). Due to the small number of patients in the groups, a correlation and regression analysis showed a weak correlation between the use of InO before allo-HSCT and the occurrence of post-transplant relapse (Pearson's contingency coefficient was 0.178). Loss of the HLA haplotype at relapse was found in 1 (4.2%) patient from the InO+ group and in 2 (6.5%) patients from the InO– group (p = n. s.). Transplant-associated thrombotic microangiopathy was diagnosed in 6 (25%) recipients in the InO+ group and in 3 (9.7%) recipients in the InO– group. Eight (32%) patients in the InO+ group and 3 (9.7%) patients in the InO– group had clinical manifestations of sinusoidal obstruction syndrome. Our study suggests the effectiveness of inotuzumab ozogamicin for the treatment of relapsed B-ALL in children before allo-HSCT. Patients with large tumor burden and high expression of CD22+ would benefit the most from therapy with InO. The application of reduced intensity conditioning regimen after CD22+ directed monoclonal antibody therapy significantly improves the overall survival rates by reducing early transplant-related mortality and makes it possible to use adoptive immunotherapy as a next line of treatment. Current allo-HSCT protocols and approaches to acute graft-versus-host disease prevention help control the development of severe complications in the early post-transplant period. Our study showed that adoptive immunotherapy via donor lymphocyte infusions can be applied in patients treated with InO who experience loss of the HLA haplotype at relapse after allo-HSCT.
- 8 July 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 60-70
Open AccessInotuzumab ozogamicin as a bridging therapy to allogeneic hematopoietic stem cell transplantation in children with refractory/relapsed B-cell acute lymphoblastic leukemia
In children with acute lymphoblastic leukemia (ALL), relapse is still the leading cause of treatment failure occurring in 10–15% of cases. Overall survival after relapse plateaus at 50–60%, whereas event-free survival after second and third relapse is approximately 25% and 15%, respectively. The introduction of new immunotherapeutic agents such as blinatumomab (a bispecific T-cell engager), inotuzumab ozogamicin (InO; a CD22+ monoclonal antibody) and a chimeric antigen T-cell receptor targeted to CD19+ can significantly increase the effectiveness of treatment for relapsed ALL and help patients achieve remission faster and thus shorten the time to allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the toxicity of these novel agents and their impact on the results of allo-HSCT are still to be investigated. Our study included 55 patients with refractory B-cell ALL aged from 3 to 17 years (the median age was 10 years). The study was approved by the Independent Ethics Committee and the Scientific Council of the I.P. Pavlov First Saint Petersburg State Medical University. The patients were divided into two groups based on whether they received inotuzumab ozogamicin or not: InO+ group (n = 24; 43.6%) and InO– group (n = 31; 56.4%). The majority of the patients underwent haploidentical HSCT (n = 53; 96.4%); 1 (1.8%) patient received HSCT from a matched related donor, and 1 (1.8%) from a matched unrelated donor. Conditioning regimens before allo-HSCT included: myeloablative conditioning (n = 20; 36.4%), reduced toxicity myeloablative conditioning (n = 5; 9.1%), and reduced intensity conditioning (n = 30; 54.5%). Acute graft-versus-host disease prophylaxis with post-transplant cyclophosphamide was given to 49 (87.7%) recipients; 6 (12.3%) patients received seroprophylaxis. Basic combined immunosuppressive therapy consisting of a calcineurin inhibitor and an mTOR inhibitor was used in 35 (63.6%) cases, and single m-TOR inhibitor treatment was administered to 20 (36.4%) patients. In the InO+ group, 21 (87.5%) patients achieved complete remission with incomplete hematologic recovery before allo-HSCT: 5 (23.8%) patients had minimal residual disease (MRD), and 16 (76.2%) patients were MRD negative. In the InO– group, remission with incomplete hematologic recovery before allo-HSCT was achieved in 15 (48.4%) patients: 3 (9.7%) cases were MRD positive and 12 (38.7%) were MRD negative (p = 0.003). All the patients underwent allo-HSCT, regardless of response to prior therapy. Engraftment was achieved in the InO+ group in 20 (83.3%) children in a median of 22 days (D+22) and in the InO– group in 25 (80.6%) children in a median of 19 days (D+19). Relapse was observed in 11 (55%) patients in the InO+ group and in 15 (60%) patients in the InO– group at a median of 164 days and 203 days post-transplant, respectively (p = n. s.). In the InO+ group, 5 (31.25%) out of 16 patients in complete remission with incomplete hematologic recovery and negative MRD status relapsed after allo-HSCT within a median of 105 days (D+58 – D+169). In the InO–, 6 (50%) out of 12 patients in complete remission with incomplete hematologic recovery and negative MRD status relapsed within a median of 296 days (D+108 – D+929). Due to the small number of patients in the groups, a correlation and regression analysis showed a weak correlation between the use of InO before allo-HSCT and the occurrence of post-transplant relapse (Pearson's contingency coefficient was 0.178). Loss of the HLA haplotype at relapse was found in 1 (4.2%) patient from the InO+ group and in 2 (6.5%) patients from the InO– group (p = n. s.). Transplant-associated thrombotic microangiopathy was diagnosed in 6 (25%) recipients in the InO+ group and in 3 (9.7%) recipients in the InO– group. Eight (32%) patients in the InO+ group and 3 (9.7%) patients in the InO– group had clinical manifestations of sinusoidal obstruction syndrome. Our study suggests the effectiveness of inotuzumab ozogamicin for the treatment of relapsed B-ALL in children before allo-HSCT. Patients with large tumor burden and high expression of CD22+ would benefit the most from therapy with InO. The application of reduced intensity conditioning regimen after CD22+ directed monoclonal antibody therapy significantly improves the overall survival rates by reducing early transplant-related mortality and makes it possible to use adoptive immunotherapy as a next line of treatment. Current allo-HSCT protocols and approaches to acute graft-versus-host disease prevention help control the development of severe complications in the early post-transplant period. Our study showed that adoptive immunotherapy via donor lymphocyte infusions can be applied in patients treated with InO who experience loss of the HLA haplotype at relapse after allo-HSCT.
- Open Access
- 1 July 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (3) , 213-224
Clinical Profile of Adults with Inherited Bone Marrow Failure Syndromes: Results of an Ambispective Clinical Single-Center Study
BACKGROUND. Inherited bone marrow failure syndromes (IBMFS) is a heterogenous group of rare genetically determined diseases with variable hematologic and nonhematologic manifestations. The implementation of highly specific methods of genetic diagnosis advanced the understanding of IBMFS and allowed its application also beyond pediatrics. That presupposes an awareness of clinical features and reference points for recognizing IBMFS in adults. AIM. To describe the clinical profile of adult IBMFS patients. MATERIALS & METHODS. This ambispective single-center study enrolled 35 patients (10 women and 25 men) with IBMFS. Patients were aged 18–51 years (median 26 years). The following IBMFS were identified: congenital dyskeratosis (n = 10; 28 %), Diamond-Blackfan anemia (n = 9; 26 %), Fanconi anemia (n = 7; 20 %), GATA2 deficiency (n = 3; 8 %), Shwachman-Diamond syndrome (n = 1; 3 %), GATA2 deficiency (n = 1; 3 %), amegakaryocytic thrombocytopenia (n = 1; 3 %), bone marrow failure syndrome type 3 (n = 1; 3 %), severe congenital neutropenia (n = 1; 3 %), bone marrow failure with SAMD9 mutation (n = 1; 3 %). These diseases were analyzed in terms of hematologic and nonhematologic manifestations as well as main diagnosis stages and factors that contribute to recognizing IBMFS. RESULTS. Monolinear cytopenia, bilinear cytopenia, and pancytopenia were identified at hematologic onset in 18 (52 %), 6 (17 %), and 11 (31 %) patients, respectively. The median age of patients by hematologic onset was 15 years (range 0–43 years), in 14 (40 %) patients cytopenia was newly diagnosed at the age of > 18 years. In 23 (63 %) patients hypocellular bone marrow was reported, 7 (20 %) and 5 (14 %) patients had pure red cell aplasia and multilineage myelodysplasia, respectively. Chromosomal aberrations were identified in 2 patients. Paroxysmal nocturnal hemoglobinuria clone was detected in none of 27 examined patients. In 12 (34 %) patients, the criteria for non-severe aplastic anemia were met. Temporary partial or complete spontaneous hematologic recovery was observed in 6 (17 %) patients. Abnormalities with partial or complete organ dysfunctions were identified in 14 patients, whereas all patients showed minor congenital defects. All 7 Fanconi anemia patients and 9 out of 10 congenital dyskeratosis patients demonstrated organ damage specific to these diseases. Family history predominantly showing malignant neoplasms in relatives was reported in 15 (43 %) patients. Initial hematological examination yielded suspect of IBMFS in 12 (34 %) patients with the median time to diagnosis of 6 months. In 23 (66 %) patients, hematologic defects with cytopenia were erroneously accounted for by various acquired diseases, which led to a delayed correct diagnosis (median 7 years). The key factors in suspecting IBMFS were organ abnormalities and positive family history. The IBMFS diagnosis was verified by the next-generation sequencing (NGS) in 29 (83 %) patients and by other specific methods in 4 (11 %) patients. In 2 patients, the diagnosis was established on the basis of complete clinical criteria alone. CONCLUSION. IBMFS is a matter of current concern and a difficult-to-recognize clinical challenge in adult hematology patients. Differential diagnosis of acquired and congenital bone marrow failure needs to be performed irrespective of patient’s age. A detailed physical examination of patients, family history, and critical analysis of clinical profile and disease course allow for early suspicion of IBMFS. Suspected IBMFS is an indication for referral of patients to specialized centers and performing genetic diagnostics including NGS.
- 1 July 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (3) , 213-224
Open AccessClinical Profile of Adults with Inherited Bone Marrow Failure Syndromes: Results of an Ambispective Clinical Single-Center Study
BACKGROUND. Inherited bone marrow failure syndromes (IBMFS) is a heterogenous group of rare genetically determined diseases with variable hematologic and nonhematologic manifestations. The implementation of highly specific methods of genetic diagnosis advanced the understanding of IBMFS and allowed its application also beyond pediatrics. That presupposes an awareness of clinical features and reference points for recognizing IBMFS in adults. AIM. To describe the clinical profile of adult IBMFS patients. MATERIALS & METHODS. This ambispective single-center study enrolled 35 patients (10 women and 25 men) with IBMFS. Patients were aged 18–51 years (median 26 years). The following IBMFS were identified: congenital dyskeratosis (n = 10; 28 %), Diamond-Blackfan anemia (n = 9; 26 %), Fanconi anemia (n = 7; 20 %), GATA2 deficiency (n = 3; 8 %), Shwachman-Diamond syndrome (n = 1; 3 %), GATA2 deficiency (n = 1; 3 %), amegakaryocytic thrombocytopenia (n = 1; 3 %), bone marrow failure syndrome type 3 (n = 1; 3 %), severe congenital neutropenia (n = 1; 3 %), bone marrow failure with SAMD9 mutation (n = 1; 3 %). These diseases were analyzed in terms of hematologic and nonhematologic manifestations as well as main diagnosis stages and factors that contribute to recognizing IBMFS. RESULTS. Monolinear cytopenia, bilinear cytopenia, and pancytopenia were identified at hematologic onset in 18 (52 %), 6 (17 %), and 11 (31 %) patients, respectively. The median age of patients by hematologic onset was 15 years (range 0–43 years), in 14 (40 %) patients cytopenia was newly diagnosed at the age of > 18 years. In 23 (63 %) patients hypocellular bone marrow was reported, 7 (20 %) and 5 (14 %) patients had pure red cell aplasia and multilineage myelodysplasia, respectively. Chromosomal aberrations were identified in 2 patients. Paroxysmal nocturnal hemoglobinuria clone was detected in none of 27 examined patients. In 12 (34 %) patients, the criteria for non-severe aplastic anemia were met. Temporary partial or complete spontaneous hematologic recovery was observed in 6 (17 %) patients. Abnormalities with partial or complete organ dysfunctions were identified in 14 patients, whereas all patients showed minor congenital defects. All 7 Fanconi anemia patients and 9 out of 10 congenital dyskeratosis patients demonstrated organ damage specific to these diseases. Family history predominantly showing malignant neoplasms in relatives was reported in 15 (43 %) patients. Initial hematological examination yielded suspect of IBMFS in 12 (34 %) patients with the median time to diagnosis of 6 months. In 23 (66 %) patients, hematologic defects with cytopenia were erroneously accounted for by various acquired diseases, which led to a delayed correct diagnosis (median 7 years). The key factors in suspecting IBMFS were organ abnormalities and positive family history. The IBMFS diagnosis was verified by the next-generation sequencing (NGS) in 29 (83 %) patients and by other specific methods in 4 (11 %) patients. In 2 patients, the diagnosis was established on the basis of complete clinical criteria alone. CONCLUSION. IBMFS is a matter of current concern and a difficult-to-recognize clinical challenge in adult hematology patients. Differential diagnosis of acquired and congenital bone marrow failure needs to be performed irrespective of patient’s age. A detailed physical examination of patients, family history, and critical analysis of clinical profile and disease course allow for early suspicion of IBMFS. Suspected IBMFS is an indication for referral of patients to specialized centers and performing genetic diagnostics including NGS.
- 3 November 2023
- Published by Wiley in Clinical Transplantation
- Vol. 38 (1) , e15181
Post‐transplant сyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia
Introduction: The data on post‐transplant cyclophosphamide (PTCy) in pediatric acute leukemia after matched allo‐HSCT are limited to case series. The present study aimed to assess the results of PTCy‐based GVHD prophylaxis in a large cohort of children with acute leukemia after matched allo‐HSCT.Methods: A retrospective analysis of 190 pediatric patients with acute leukemia who had a first allograft between 2008 and 2020 from a matched sibling donor (MSD) or matched unrelated donor (MUD) was carried out. In the MSD setting, GVHD prophylaxis consisted of PTCy alone (n = 28) for the study group, and calcineurin inhibitor (CNI) ± antimetabolite (n = 30) for the control group. In MUD setting, most patients in the study group received GVHD prophylaxis with PTCy+CNI+mycophenolate mofetil (n = 42, 66.7%) or PTCy+CNI+sirolimus (n = 12, 19%). All patients (n = 69) in the control group received ATG+CNI+antimetabolite.Results: After MUD allo‐HSCT, the incidences of acute GVHD grade III‐IV and moderate/severe chronic GVHD were significantly lower in the PTCy group compared to control (6.6% vs. 35.0% and 12.7% vs. 47.1%, respectively, p < .0001). Five‐year GVHD‐free, relapse‐free survival (GRFS) after MUD allo‐HSCT was higher in the PTCy group compared to control (35.1% vs. 7.3%, p < .0001). At the same time, there was no significant difference between both groups after MSD allo‐HSCT.Conclusions: In pediatric acute leukemia, PTCy‐based GVHD prophylaxis for MUD allo‐HSCT is a feasible and effective option that results in a low incidence of GVHD. Compared to the ATG‐based approach, PTCy provides better control of GVHD in children. In pediatric allo‐HSCT from MSD, PTCy demonstrates comparable effectiveness to conventional GVHD prophylaxis.
- 3 November 2023
- Published by Wiley in Clinical Transplantation
- Vol. 38 (1) , e15181
Post‐transplant сyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia
Introduction: The data on post‐transplant cyclophosphamide (PTCy) in pediatric acute leukemia after matched allo‐HSCT are limited to case series. The present study aimed to assess the results of PTCy‐based GVHD prophylaxis in a large cohort of children with acute leukemia after matched allo‐HSCT.Methods: A retrospective analysis of 190 pediatric patients with acute leukemia who had a first allograft between 2008 and 2020 from a matched sibling donor (MSD) or matched unrelated donor (MUD) was carried out. In the MSD setting, GVHD prophylaxis consisted of PTCy alone (n = 28) for the study group, and calcineurin inhibitor (CNI) ± antimetabolite (n = 30) for the control group. In MUD setting, most patients in the study group received GVHD prophylaxis with PTCy+CNI+mycophenolate mofetil (n = 42, 66.7%) or PTCy+CNI+sirolimus (n = 12, 19%). All patients (n = 69) in the control group received ATG+CNI+antimetabolite.Results: After MUD allo‐HSCT, the incidences of acute GVHD grade III‐IV and moderate/severe chronic GVHD were significantly lower in the PTCy group compared to control (6.6% vs. 35.0% and 12.7% vs. 47.1%, respectively, p < .0001). Five‐year GVHD‐free, relapse‐free survival (GRFS) after MUD allo‐HSCT was higher in the PTCy group compared to control (35.1% vs. 7.3%, p < .0001). At the same time, there was no significant difference between both groups after MSD allo‐HSCT.Conclusions: In pediatric acute leukemia, PTCy‐based GVHD prophylaxis for MUD allo‐HSCT is a feasible and effective option that results in a low incidence of GVHD. Compared to the ATG‐based approach, PTCy provides better control of GVHD in children. In pediatric allo‐HSCT from MSD, PTCy demonstrates comparable effectiveness to conventional GVHD prophylaxis.
- Open Access
- 30 September 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (3) , 28-35
A successful second allogeneic hematopoietic stem cell transplantation from an alternative donor in a patient with loss of HLA heterozygosity relapse of juvenile myelomonocytic leukemia: case series analysis
Juvenile myelomonocytic leukemia (JMML) is a rare and aggressive myeloproliferative/myelodysplastic neoplasm of early childhood characterized by activation of the Ras signaling pathway. Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only proven curative treatment for JMML. However, the 5-year overall survival is about 52–64%. In this work, we analyzed 4 clinical cases of patients with relapses of JMML with loss of heterozygosity in HLA (LoH) after allo-HSCT. The patients' parents gave their consent to the use of their children's data, including photographs, for research purposes and in publications. Two patients received a second allo-HSCT from an alternative donor, two patients – from the same donor. A positive result in the form of a durable remission was observed in one patient who underwent a second allo-HSCT from an alternative donor and restored HLA genetic heterozygosity. At the same time, immunotherapy with infusions of donor lymphocytes led to the development of graft-versus-host disease without potentiating the antileukemic effect. Thus, a second allo-HSCT from an alternative donor for the treatment of relapsed JMML with HLA LoH is necessary to restore the “graft-versus-JMML” response. The study was approved by the Independent Ethics Committee and the Scientific Council of the I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation.
- 30 September 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (3) , 28-35
Open AccessA successful second allogeneic hematopoietic stem cell transplantation from an alternative donor in a patient with loss of HLA heterozygosity relapse of juvenile myelomonocytic leukemia: case series analysis
Juvenile myelomonocytic leukemia (JMML) is a rare and aggressive myeloproliferative/myelodysplastic neoplasm of early childhood characterized by activation of the Ras signaling pathway. Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only proven curative treatment for JMML. However, the 5-year overall survival is about 52–64%. In this work, we analyzed 4 clinical cases of patients with relapses of JMML with loss of heterozygosity in HLA (LoH) after allo-HSCT. The patients' parents gave their consent to the use of their children's data, including photographs, for research purposes and in publications. Two patients received a second allo-HSCT from an alternative donor, two patients – from the same donor. A positive result in the form of a durable remission was observed in one patient who underwent a second allo-HSCT from an alternative donor and restored HLA genetic heterozygosity. At the same time, immunotherapy with infusions of donor lymphocytes led to the development of graft-versus-host disease without potentiating the antileukemic effect. Thus, a second allo-HSCT from an alternative donor for the treatment of relapsed JMML with HLA LoH is necessary to restore the “graft-versus-JMML” response. The study was approved by the Independent Ethics Committee and the Scientific Council of the I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation.
- Open Access
Trends in Outcome of Hematopoietic Stem Cell Transplantation: 5000 Transplantations and 30 Years of Single-Center Experience
In this single-center analysis, we evaluated the trends in 5185 hematopoietic cell transplantations performed between 1990 and 2022. The study group comprised 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) hematopoietic cell transplantations. In the multivariate analysis, there was an improvement in event-free-survival (EFS) after autoHCT (HR 0.6, 95% CI 0.4–0.7, p < 0.0001) due to reduced cumulative incidence of relapse in the last five years (56% in 2010–2014 vs. 38% in 2015–2022). An improvement in EFS after alloHCT over time was observed (HR 0.33, 95% CI 0.23–0.48, p < 0.0001), which was due to reduced non-relapse mortality. No difference in cumulative relapse incidence was observed over the last decade for allografted patients. Survival after autoHCT improved in Hodgkin’s disease (HR 0.1, 95% CI 0.1–0.3), multiple myeloma (HR 0.4, 95% CI 0.2–0.7) and solid tumors (HR 0.2, 95% CI 0.2–0.4), while after alloHCT, improvement was observed in acute myeloid leukemia (HR 0.3, 95% CI 0.1–0.5), acute lymphoblastic leukemia (HR 0.2, 95% CI 0.1–0.5), Hodgkin’s disease (HR 0.1, 95% CI 0.0–0.4), non-Hodgkin’s lymphomas and chronic lymphocytic leukemia (HR 0.2, 95% CI 0.0–0.6), inborn diseases (HR 0.2, 95% CI 0.2–0.4) and acquired aplastic anemia with matched related donors and matched unrelated donors (HR 0.3, 95% CI 0.2–0.8).
Open AccessTrends in Outcome of Hematopoietic Stem Cell Transplantation: 5000 Transplantations and 30 Years of Single-Center Experience
In this single-center analysis, we evaluated the trends in 5185 hematopoietic cell transplantations performed between 1990 and 2022. The study group comprised 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) hematopoietic cell transplantations. In the multivariate analysis, there was an improvement in event-free-survival (EFS) after autoHCT (HR 0.6, 95% CI 0.4–0.7, p < 0.0001) due to reduced cumulative incidence of relapse in the last five years (56% in 2010–2014 vs. 38% in 2015–2022). An improvement in EFS after alloHCT over time was observed (HR 0.33, 95% CI 0.23–0.48, p < 0.0001), which was due to reduced non-relapse mortality. No difference in cumulative relapse incidence was observed over the last decade for allografted patients. Survival after autoHCT improved in Hodgkin’s disease (HR 0.1, 95% CI 0.1–0.3), multiple myeloma (HR 0.4, 95% CI 0.2–0.7) and solid tumors (HR 0.2, 95% CI 0.2–0.4), while after alloHCT, improvement was observed in acute myeloid leukemia (HR 0.3, 95% CI 0.1–0.5), acute lymphoblastic leukemia (HR 0.2, 95% CI 0.1–0.5), Hodgkin’s disease (HR 0.1, 95% CI 0.0–0.4), non-Hodgkin’s lymphomas and chronic lymphocytic leukemia (HR 0.2, 95% CI 0.0–0.6), inborn diseases (HR 0.2, 95% CI 0.2–0.4) and acquired aplastic anemia with matched related donors and matched unrelated donors (HR 0.3, 95% CI 0.2–0.8).
- Open Access
- 8 July 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (2) , 44-53
The prognostic value of HLA loss of heterozygosity after allogeneic hematopoietic stem cell transplantation in children with relapsed acute leukemia
The loss of a patient-specific HLA haplotype on the surface of the blast cell population is one of the ways a tumor can evade the immune surveillance of donor cells. This phenomenon is observed in approximately 30 % of relapses in patients with hematologic malignancies who underwent partially mismatched allogeneic hematopoietic stem cell transplantation (HSCT). In this study, for the first time, a large cohort of pediatric patients (n = 80) with relapsed acute myeloid (AML) or acute lymphoblastic (ALL) leukemia after allogeneic HSCT was analyzed with the help of the STR method (highlypolymorphic microsatellite marker analysis) using 6 HLA haplotype markers. The study was approved by the Independent Ethics Committee and the Scientific Council of the I. P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation. Loss of heterozygosity (LOH) was observed in 18 / 80 (22 %) relapsed patients with various types of acute leukemia: out of these, 8 / 44 (18 %) patients had B-cell ALL, 4 / 10 (40 %) patients – T-cell ALL and 6 / 25 (24 %) patients – AML. All relapses with LOH were observed in patients who had undergone haploidentical HSCT, and were found to occur later than relapses without loss of the HLA haplotype (median time to relapse: 8.8 months vs 6.2 months, p = 0.043). In the patients treated with haploidentical HSCT (n = 61), we assessed factors increasing the risk of LOH at relapse. The number of previous therapy lines in the patients with AML (n = 17) and acute or chronic graft-versus-host disease in the patients with ALL (n = 44) were associated with an increasedrisk of genetic loss of the HLA haplotype (p = 0.008 and p = 0.015 respectively). A relapse following the second allogeneic HSCT was associated with LOH in 4 / 5 (80 %) patients, p = 0.008. The prognosis of the patients with LOH was extremely poor. At a median follow-up of 6 months, the overall survival from relapse was 22 % in the LOH group and 37 % in the non-LOH group. The median overall survival was 4.5 months (95 % confidence interval 3–NA) and 10.3 months (95 % confidence interval 5.7–16.1) respectively, p = 0.063. Among the patients with LOH, the best survival rates were observed in those who had undergone a repeat allogeneic HSCT from a different donor. Thus, the analysis of LOH is an important tool for determining the prognosis and further treatment in pediatric patients with acute leukemias. We strongly recommend that this diagnostic test should be included into standard testing of patients after partially-mismatched allogeneic HSCT.
- 8 July 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (2) , 44-53
Open AccessThe prognostic value of HLA loss of heterozygosity after allogeneic hematopoietic stem cell transplantation in children with relapsed acute leukemia
The loss of a patient-specific HLA haplotype on the surface of the blast cell population is one of the ways a tumor can evade the immune surveillance of donor cells. This phenomenon is observed in approximately 30 % of relapses in patients with hematologic malignancies who underwent partially mismatched allogeneic hematopoietic stem cell transplantation (HSCT). In this study, for the first time, a large cohort of pediatric patients (n = 80) with relapsed acute myeloid (AML) or acute lymphoblastic (ALL) leukemia after allogeneic HSCT was analyzed with the help of the STR method (highlypolymorphic microsatellite marker analysis) using 6 HLA haplotype markers. The study was approved by the Independent Ethics Committee and the Scientific Council of the I. P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation. Loss of heterozygosity (LOH) was observed in 18 / 80 (22 %) relapsed patients with various types of acute leukemia: out of these, 8 / 44 (18 %) patients had B-cell ALL, 4 / 10 (40 %) patients – T-cell ALL and 6 / 25 (24 %) patients – AML. All relapses with LOH were observed in patients who had undergone haploidentical HSCT, and were found to occur later than relapses without loss of the HLA haplotype (median time to relapse: 8.8 months vs 6.2 months, p = 0.043). In the patients treated with haploidentical HSCT (n = 61), we assessed factors increasing the risk of LOH at relapse. The number of previous therapy lines in the patients with AML (n = 17) and acute or chronic graft-versus-host disease in the patients with ALL (n = 44) were associated with an increasedrisk of genetic loss of the HLA haplotype (p = 0.008 and p = 0.015 respectively). A relapse following the second allogeneic HSCT was associated with LOH in 4 / 5 (80 %) patients, p = 0.008. The prognosis of the patients with LOH was extremely poor. At a median follow-up of 6 months, the overall survival from relapse was 22 % in the LOH group and 37 % in the non-LOH group. The median overall survival was 4.5 months (95 % confidence interval 3–NA) and 10.3 months (95 % confidence interval 5.7–16.1) respectively, p = 0.063. Among the patients with LOH, the best survival rates were observed in those who had undergone a repeat allogeneic HSCT from a different donor. Thus, the analysis of LOH is an important tool for determining the prognosis and further treatment in pediatric patients with acute leukemias. We strongly recommend that this diagnostic test should be included into standard testing of patients after partially-mismatched allogeneic HSCT.